IRadimed Stock Up 80% in One Year as Fund Sells $29 Million Stake Amid Record Quarter
Nine Ten Capital Management sold 342,907 shares of IRadimed (NASDAQ:IRMD), valued at an estimated $29.42 million, during the fourth quarter of 2025. Despite the sale, IRadimed's stock has risen 83% over the past year, reflecting its strong financial performance, including 18 consecutive quarters of record revenue and increased dividends. The fund's decision to trim its stake is attributed to portfolio discipline rather than a lack of confidence in the company's fundamentals, as it still represents 13.2% of their assets under management.
Allen Monty K sells IRADIMED (IRMD) shares worth $100,256 By Investing.com
Director Allen Monty K has sold 1,000 shares of IRADIMED (NASDAQ:IRMD) for a total of $100,256, with shares trading near their 52-week high and showing an 83.6% return over the past year. Despite a strong financial health rating and expected profitability, InvestingPro suggests the stock may be overvalued with a P/E ratio of 57.5. This transaction follows the company's impressive fourth-quarter 2025 earnings, which exceeded analyst expectations.
Allen Monty K sells IRADIMED (IRMD) shares worth $100,256
Director Allen Monty K sold 1,000 shares of IRADIMED CORP (NASDAQ:IRMD) for $100,256 on February 13, 2026. This transaction occurred as the stock trades near its 52-week high and has shown an 83.6% return over the past year. Despite a P/E ratio of 57.5, suggesting potential overvaluation, the company recently reported strong fourth-quarter 2025 earnings, exceeding analyst expectations.
Director Monty Allen Sells 1,000 Shares of iRadimed Corp (IRMD)
Monty Allen, a Director at iRadimed Corp (IRMD), sold 1,000 shares of the company on February 13, 2026, reducing his holdings to 21,000 shares. This transaction follows a pattern of 26 insider sells and no buys over the past year. The stock is currently trading at $100.26, indicating it is significantly overvalued with a price-to-GF-Value ratio of 1.67 and a P/E ratio of 57.03 compared to an industry median of 28.48.
IRADIMED Record Revenue Streak Supports 3870 Pump Rollout And Dividend Growth
IRADIMED (NasdaqGM:IRMD) announced its 18th consecutive quarter of record revenue and the full rollout of its 3870 MRI compatible IV infusion pump, alongside an increased quarterly dividend. The company has shown strong stock performance over the past five years, and the new pump is expected to drive further growth in Europe and Japan. While analysts see potential, Simply Wall St's valuation indicates the stock is currently trading significantly above its estimated fair value.
IRADIMED Dividend Hike Follows Record Revenue And New MRI Pump Rollout
IRADIMED (NasdaqGM:IRMD) announced an increased quarterly dividend to US$0.20 per share, following 18 consecutive quarters of record revenue and strong double-digit growth in sales and earnings. The company is experiencing robust adoption of its existing MRI-compatible devices and is shipping its new 3870 infusion pump, with management confident in future product launches and domestic replacement demand. While the dividend hike signals strong financial health, investors are advised to monitor the rollout and potential competitive pressures, especially given recent insider selling.
Iradimed Corp Eyes 2026 Surge After Strong Quarter
Iradimed Corp reported record Q4 2025 revenue of $22.7 million, up 17% year over year, with full-year sales reaching $83.8 million, a 14% increase. The company is launching its new 3870 MR IV pump, expecting a 10%-14% higher average selling price and targeting a $100 million-plus revenue run rate in 2026 from the significant U.S. replacement market. While the transition may bring near-term margin pressure and international launch delays, the company is optimistic about sustained growth and future R&D in a next-generation MRI monitor.
IRadimed Corporation (NASDAQ:IRMD) Q4 2025 Earnings Call Transcript
IRadimed Corporation reported record revenues of $22.7 million in Q4 2025, a 17% increase year-over-year, and $83.8 million for the full year 2025. The company's new 3870 MR IV pump is expected to be a significant growth driver, targeting a large replacement opportunity in the U.S. market. IRadimed anticipates reaching a $100 million-plus annual revenue run rate during 2026, driven by the new pump and continued growth in other product lines.
iRadimed Corporation (NASDAQ:IRMD) to Issue Quarterly Dividend of $0.20
iRadimed Corporation (NASDAQ:IRMD) declared a quarterly dividend of $0.20 per share, a 17.6% increase from its previous dividend, resulting in an 0.8% yield. The medical equipment provider's shares rose by 9.3% after reporting better-than-expected Q4 earnings of $0.54 EPS on revenues of $22.69 million. The company also provided strong guidance for Q1 and FY2026, indicating sufficient coverage for the increased dividend.
IRADIMED CORPORATION Reports Record Fourth Quarter and Full
IRADIMED CORPORATION announced record financial results for the fourth quarter and full year of 2025, with revenue reaching $22.7 million for Q4 (17% increase) and $83.8 million for the full year (14% increase). The company also increased its regular quarterly cash dividend to $0.20 per share, reflecting confidence in its business outlook. This growth was driven by the successful shipment of initial 3870 units and expected full rollout of the next-generation MRI-compatible IV infusion pump in early 2026, alongside positive financial guidance for 2026.
Iradimed Stock Surges as Record Quarterly Revenue Streak Hits 18
Iradimed Corporation (IRMD) shares surged by 9.26% after reporting its 18th consecutive quarter of record revenue, reaching $22.7 million in Q4 2025 – a 17% increase year-over-year. Non-GAAP net income also grew by 23% to $7.0 million, or $0.54 per share, surpassing analyst expectations. The company also announced an increased quarterly dividend and provided optimistic revenue guidance for 2026, projecting $91 million to $96 million.
IRadimed: Fourth Quarter Financial Highlights
IRadimed Corp. announced a net profit of $6.4 million for the fourth quarter, with earnings of 50 cents per share and adjusted earnings of 54 cents per share. The company, which manufactures IV devices for MRI equipment, achieved $22.7 million in revenue for the quarter and $83.8 million for the full year. For the upcoming first quarter, IRadimed anticipates earnings per share between 44 and 48 cents, with projected revenue of $21 million to $22 million.
IRadimed: Fourth Quarter Financial Highlights
IRadimed Corp. announced its fourth-quarter financial results, reporting a net income of $6.4 million and adjusted earnings of 54 cents per share on $22.7 million in revenue. For the full year, the company achieved a net profit of $22.5 million and $83.8 million in total revenue. IRadimed projects first-quarter earnings per share between 44 and 48 cents and revenue between $21 million and $22 million.
IRADIMED CORPORATION Reports Record Fourth Quarter and Full Year of 2025 Financial Results
IRADIMED CORPORATION announced record financial results for the fourth quarter and full year of 2025, driven by strong operational performance and strategic initiatives. The company reported significant increases in revenue and diluted EPS, successfully launched its next-generation MRI-compatible IV infusion pump, and declared an increased quarterly cash dividend. IRADIMED also provided an optimistic outlook for revenue and EPS for the first quarter and full year of 2026.
IRadimed: Q4 Earnings Snapshot
IRadimed Corp. (IRMD) reported a net income of $6.4 million, or 50 cents per share, in its fourth quarter, with adjusted earnings of 54 cents per share. The company generated revenue of $22.7 million for the period. For the full year, IRadimed's profit was $22.5 million, or $1.75 per share, on $83.8 million in revenue, and it provided a first-quarter earnings outlook of 44 to 48 cents per share on revenue between $21 million and $22 million.
IRadimed: Fourth Quarter Financial Highlights
IRadimed Corp. reported a net profit of $6.4 million for the fourth quarter, with earnings of 50 cents per share and adjusted earnings of 54 cents per share, on revenue of $22.7 million. For the full year, the company achieved a profit of $22.5 million ($1.75 per share) and $83.8 million in revenue. Looking ahead, IRadimed forecasts first-quarter earnings per share between 44 and 48 cents and revenue of $21 million to $22 million.
Analysts Are Bullish on Top Healthcare Stocks: Iradimed (IRMD), Inotiv (NOTV)
Two healthcare stocks, Iradimed (IRMD) and Inotiv (NOTV), have received bullish sentiments from analysts. Frank Takkinen from Lake Street reiterated a Buy rating on Iradimed with a $100.00 price target, while Matt Hewitt from Craig-Hallum maintained a Buy rating on Inotiv. Both companies currently hold a Moderate Buy consensus among analysts.
Ranger Investment Management L.P. Lowers Stake in iRadimed Corporation $IRMD
Ranger Investment Management L.P. significantly reduced its stake in iRadimed Corporation (NASDAQ:IRMD) by 44.3% in the third quarter, selling over 95,000 shares. Despite this, other institutional investors have either increased or initiated positions in the medical equipment provider. iRadimed, with a market capitalization of $1.22 billion, recently beat EPS estimates, paid a special dividend, and maintains a "Moderate Buy" consensus rating among analysts, even as company insiders have sold shares.
The total return for IRADIMED (NASDAQ:IRMD) investors has risen faster than earnings growth over the last five years
IRADIMED (NASDAQ:IRMD) shareholders have seen a 280% price increase over five years, accompanied by 38% annual EPS growth. However, the total shareholder return (TSR), which includes reinvested dividends, was even higher at 316% over the same period, indicating dividends played a significant role. Recently, the one-year TSR of 57% has surpassed the five-year average, suggesting improved sentiment around the company.
IRADIMED CORPORATION to Hold Fourth Quarter and Full Year 2025 Financial Results Conference Call on February 10, 2026
IRADIMED CORPORATION (NASDAQ: IRMD) will announce its fourth quarter and full year 2025 financial results before the market opens on Tuesday, February 10, 2026. Company management will host a conference call on the same day at 11:00 a.m. Eastern Time to discuss the results and answer questions. Investors can register online for dial-in details or access a real-time webcast, with a recording to be made available on the company's investor website afterward.
Insider Transaction: Roger E Susi Sells $503K Worth Of iRadimed Shares
Roger E Susi, CEO of iRadimed (NASDAQ: IRMD), sold 5,000 shares of the company's stock for a total of $503,255 on January 27, according to an SEC filing. Despite this insider sale, iRadimed has demonstrated strong financial performance, including a 15.69% revenue growth and a high gross margin of 77.8%, though its market capitalization is smaller than industry peers. Insider transactions can be an important factor for investors to consider, with sales not always indicating a bearish outlook.
iRadimed (NASDAQ:IRMD) CEO Sells $503,250.00 in Stock
iRadimed CEO Roger Susi sold 5,000 shares of the company's stock for $503,250 on January 26th, reducing his direct ownership by 0.22% while still holding over 2.2 million shares. The medical equipment provider recently reported strong quarterly earnings, beating analyst estimates, and announced a special dividend. The stock currently trades at $99.84 with a "Moderate Buy" analyst rating and a target price of $95.00.
IRADIMED Corp (NASDAQ:IRMD) Emerges as a Top Quality Stock from the Caviar Cruise Screen
IRADIMED Corp (NASDAQ:IRMD) has been identified as a top-quality stock through the "Caviar Cruise" stock screen, which focuses on companies with durable competitive strengths, sound financial conditions, and high returns on capital. The company, specializing in MRI-compatible medical devices, exhibits exceptional profitability with a 46.8% ROIC, a debt-free balance sheet, and strong earnings quality, reinforcing its position as an attractive long-term investment. Its fundamental assessment highlights excellent profitability and financial health, despite a valuation that reflects its high-grade growth profile.
How Record Q3 Results And FDA-Cleared MRI Pump Launch At IRADIMED (IRMD) Has Changed Its Investment Story
IRADIMED (IRMD) experienced a significant boost after reporting record Q3 2025 revenue of US$21.2 million and receiving FDA approval for its MRI-compatible 3870 IV infusion pump in July 2025. This has led to raised full-year revenue and EPS guidance, along with a special dividend, though a high valuation and insider selling suggest elevated expectations. The article examines how the new pump impacts IRADIMED's investment outlook, highlighting both opportunities and risks, such as potential shifts in sentiment if commercialization falters.
Insider Selling: iRadimed (NASDAQ:IRMD) CEO Sells 5,000 Shares of Stock
iRadimed (NASDAQ:IRMD) CEO Roger Susi sold 5,000 shares of the company's stock on January 20th at an average price of $101.84, totaling $509,200. This transaction reduced his position by 0.22%, though he still owns 2,267,500 shares. The company's stock recently traded near its 52-week high, and reported strong quarterly earnings, beating analyst estimates, and announced a special dividend.
iRadimed Corporation (NASDAQ:IRMD) Given Average Rating of "Moderate Buy" by Analysts
MarketBeat reports that five research firms have given iRadimed Corporation (NASDAQ:IRMD) an average "Moderate Buy" rating, with a mean one-year price target of $87.33. Despite recent insider selling from CFO John Glenn and CEO Roger Susi, insiders still own 36.8% of the company. iRadimed recently beat Q3 EPS estimates, provided positive FY2025 EPS guidance, and paid a special dividend.
iRadimed Corporation (NASDAQ:IRMD) Short Interest Update
iRadimed Corporation (NASDAQ:IRMD) saw a significant 25.1% increase in short interest during December, reaching 388,071 shares, representing about 4.8% of the float. Despite this, the company reported strong Q3 earnings, beating analyst estimates, and has provided positive EPS guidance for Q4 2025 and FY 2025. Insider selling by the CEO and CFO has been noted, although insiders collectively still own a substantial portion of the company's stock.
iRadimed (NASDAQ:IRMD) Reaches New 52-Week High - Here's Why
iRadimed (NASDAQ:IRMD) recently hit a new 52-week high of $101.00, trading up approximately 2.9% with a market capitalization of $1.3 billion. Despite a "Moderate Buy" consensus rating from analysts, the average price target of $87.33 is below the current share price. The company reported strong quarterly earnings, beating estimates, and insiders sold about 60,000 shares last quarter, though they still own a substantial portion of the company's stock.
Insider Selling: iRadimed (NASDAQ:IRMD) CEO Sells 5,000 Shares of Stock
iRadimed's CEO, Roger Susi, sold 5,000 shares of IRMD stock on January 12th for a total of $487,250, reducing his stake by 0.22%. Despite the insider selling, the company has recently reported strong financial performance, beating quarterly EPS expectations and issuing positive FY2025 guidance. The stock is currently trading near its 12-month high with a market capitalization of $1.26 billion.
Iradimed stock hits all-time high at 100.55 USD
Iradimed Corporation's stock reached an all-time high of 100.55 USD, reflecting significant investor confidence and strong company performance. The medical device company, with a market capitalization of $1.28 billion, has seen its stock price increase by 75.29% over the last year. Despite the surge, InvestingPro analysis suggests the stock might be overvalued, and the company is scheduled to report earnings in 15 days.
Iradimed CEO Susi sells $487k in shares By Investing.com
Iradimed CEO Roger E. Susi sold a total of 5,000 shares of IRADIMED CORP (NASDAQ:IRMD) for approximately $487,126.64 on January 12, 2026. These sales were part of a pre-arranged trading plan. This news follows iRadimed Corporation's strong Q3 2025 earnings, which surpassed analyst expectations, and the announcement of a special cash dividend.
Iradimed CEO Susi sells $487k in shares By Investing.com
IRADIMED CORP CEO Roger E. Susi sold a total of 5,000 shares of common stock for approximately $487,126, executed under a pre-arranged Rule 10b5-1 trading plan. Following these transactions, Susi indirectly holds 2,272,500 shares. The company recently reported strong Q3 2025 earnings, surpassing analyst expectations, and announced a special cash dividend of $0.50 per share.
Iradimed CEO Susi sells $487k in shares
Iradimed CEO Roger E. Susi sold 4,888 shares and 112 shares of common stock on January 12, 2026, totaling $487,126.64. These sales were executed under a pre-arranged Rule 10b5-1 trading plan. The company recently reported Q3 2025 earnings exceeding analyst expectations and announced a special cash dividend of $0.50 per share.
Iradimed CEO Susi sells $487k in shares
Iradimed CEO Roger E. Susi sold 4,888 shares and 112 shares of IRADIMED CORP common stock on January 12, 2026, totaling over $487,000. These transactions were carried out under a pre-arranged Rule 10b5-1 trading plan. Following the sale, Susi indirectly holds 2,272,500 shares through a family trust.
Iradimed Co stock hits all-time high at 99.72 USD
Iradimed Co (IRMD) stock has soared to an all-time high of $99.72, showcasing a strong performance with a 74.75% increase over the last year and a 56.02% gain in the past six months. This surge follows iRadimed Corporation's strong Q3 2025 earnings, which surpassed analyst expectations, and the approval of a special cash dividend of $0.50 per share.
Insider Unloading: Roger E Susi Sells $488K Worth Of iRadimed Shares
Roger E Susi, CEO of iRadimed (NASDAQ: IRMD), recently sold 5,000 shares of the company, totaling $488,316, according to an SEC filing on December 30. The article details iRadimed's financial performance, including a 15.69% revenue growth, a 77.8% gross margin, and an EPS of 0.44, alongside market valuation metrics like a P/E ratio of 59.25. It emphasizes that insider transactions offer valuable insights but should not be the sole basis for investment decisions.
iRadimed (NASDAQ:IRMD) CEO Roger Susi Sells 5,000 Shares
iRadimed CEO Roger Susi sold 5,000 shares of the company's stock, totaling $488,300, reducing his ownership by 0.22%. Despite the sale, iRadimed has shown strong performance, beating Q3 earnings estimates and declaring a special dividend of $0.50 per share. The company's shares are trading near a 12-month high, reflecting positive investor sentiment.
Copeland Capital Management LLC Has $30.85 Million Holdings in iRadimed Corporation $IRMD
Copeland Capital Management LLC has reduced its stake in iRadimed Corporation (NASDAQ:IRMD) by 5.3% in Q3, now holding 433,500 shares valued at $30.85 million. iRadimed surpassed Q3 earnings estimates and provided optimistic Q4 and full-year 2025 guidance, while also declaring a special dividend of $0.50. Despite recent insider selling, institutional investors and hedge funds own 92.34% of the stock, and analysts maintain a "Moderate Buy" rating with a consensus target price of $87.33.
Rice Hall James & Associates LLC Reduces Position in iRadimed Corporation $IRMD
Rice Hall James & Associates LLC reduced its stake in iRadimed Corporation by 31.9% in Q3, bringing its holdings to 43,593 shares worth approximately $3.10 million. Despite significant insider selling totaling $5.55 million in the last 90 days, institutional investors collectively own about 92.34% of the company's stock. Analysts currently rate iRadimed as a "Moderate Buy" with a consensus price target of $87.33, following recent strong earnings and a special dividend announcement.
iRadimed Corporation (NASDAQ:IRMD) Receives Average Recommendation of "Moderate Buy" from Brokerages
iRadimed Corporation (NASDAQ:IRMD) has received an average "Moderate Buy" recommendation from five analysts, with a one-year average target price of $87.33. Recent insider selling totaled 65,000 shares worth $5.55M, though insiders still hold a significant 36.80% of the company's stock. The company exceeded Q3 earnings estimates, and announced a special dividend of $0.50 per share payable on December 30th.
IRADIMED's (NASDAQ:IRMD) investors will be pleased with their incredible 352% return over the last five years
IRADIMED CORPORATION (NASDAQ:IRMD) shareholders have achieved an impressive 352% return over the last five years, largely attributed to the company's strong earnings per share growth of 38% annually. This positive sentiment highlights how well-performing businesses can significantly reward long-term investors. The total shareholder return (TSR) includes dividend payments, which further boosted the overall return compared to just the share price increase.
Insider Decision: Roger E Susi Offloads $483K Worth Of iRadimed Stock
Roger E Susi, CEO of iRadimed (NASDAQ: IRMD), sold 5,000 shares of the company's stock for a total of $483,671, according to an SEC filing on December 22. The article also provides a financial overview of iRadimed, highlighting its revenue growth, profitability metrics, debt management, and valuation metrics. Insider transactions, particularly open market sales, are discussed as an important factor for investors to consider.
Iradimed stock reaches all-time high at 98.24 USD By Investing.com
Iradimed Co (IRMD) stock has reached an all-time high of $98.24, close to its 52-week high of $98.44, reflecting robust growth over the past year. The company has a market capitalization of $1.25 billion and an 80.67% increase over the past year, with a 68.49% gain in the last six months. InvestingPro's analysis suggests the stock might be overvalued with a P/E ratio of 58.94.
Iradimed stock reaches all-time high at 98.24 USD
Iradimed Co (IRMD) stock has reached an all-time high of $98.24, reflecting a strong growth period and an 80.67% increase over the past year. Despite its robust performance and "GREAT" financial health score, InvestingPro analysis suggests the stock might be overvalued with a P/E ratio of 58.94. The company recently surpassed Q3 2025 earnings expectations and announced a special cash dividend of $0.50 per share.
iRadimed (NASDAQ:IRMD) CEO Sells 5,000 Shares
iRadimed CEO Roger Susi sold 5,000 shares of the company stock on December 22nd at an average price of $96.73, totaling $483,650. This transaction reduced his ownership stake by 0.22%. The company recently declared a special dividend of $0.50 per share, payable on December 30th to shareholders of record as of December 17th.
Is IRADIMED’s US$0.50 Special Dividend Reshaping the Investment Case for IRMD?
IRADIMED Corporation recently declared a special cash dividend of US$0.50 per share, payable on December 30, 2025. This one-off payout underscores the company's financial flexibility and its ability to return excess cash to shareholders, reinforcing its investment narrative focused on MRI-compatible devices and recurring revenue. While the special dividend highlights balance sheet strength, the company's future investment case still heavily relies on the successful adoption of its 3870 pump and managing concentration risk within its product lineup.
IRADIMED (IRMD): Assessing Valuation After Strong Multi‑Year Share Price Gains
IRADIMED (IRMD) has shown significant share price appreciation over the past five years, outperforming many healthcare peers, with recent gains of 86% in the last year and 3.5x over five years. Despite its strong performance and being considered modestly undervalued by a popular narrative with a fair value near $99, analysts have a consensus price target of $73.50, based on projections for revenue, earnings, and PE ratio by 2028. However, an alternative view suggests that the current rich multiples, trading at 58 times earnings compared to the US medical equipment group's 30 times, indicate valuation risk if growth slows.
IRADIMED (IRMD): Assessing Valuation After Strong Multi‑Year Share Price Gains
IRADIMED (IRMD) has shown significant share price gains, with an 86% increase over the past year and roughly 3.5x over five years. The company is currently trading near analyst targets, with a narrative fair value suggesting modest upside, despite some valuation risks due to rich multiples compared to the industry average. Investors are questioning whether future growth is already priced in, warranting a deeper analysis of the company's financials and potential risks.
Ranger Investment Management L.P. Increases Holdings in iRadimed Corporation $IRMD
Ranger Investment Management L.P. has increased its stake in iRadimed Corporation (NASDAQ:IRMD) by 7.4%, bringing its total holdings to 214,840 shares, representing about 1.69% ownership. This comes as institutional investors now collectively own approximately 92.34% of the company's stock. Despite positive financial news, including a dividend announcement and an earnings beat, company insiders have recently sold a significant amount of shares.
Insider Sell: James Hawkins Sells 3,000 Shares of iRadimed Corp (IRMD)
James Hawkins, a Director at iRadimed Corp (IRMD), sold 3,000 shares on December 9, 2025, reducing his holdings to 28,742 shares. This transaction follows a total of 6,000 shares sold by Hawkins over the past year, with no purchases. iRadimed Corp's stock, trading at $96.61, is deemed significantly overvalued with a price-to-GF-Value ratio of 1.64.
